Lexeo Therapeutics
Overview
flowchart TD
therapeutics["therapeutics"] -->|"protects against"| age_related_cognitive_decline["age-related cognitive decline"]
therapeutics["therapeutics"] -->|"inhibits"| neuroinflammation["neuroinflammation"]
Therapeutics["Therapeutics"] -->|"references"| SIRT6["SIRT6"]
Therapeutics["Therapeutics"] -->|"references"| AADC["AADC"]
Therapeutics["Therapeutics"] -->|"references"| CX3CR1["CX3CR1"]
Therapeutics["Therapeutics"] -->|"references"| BACE1["BACE1"]
Therapeutics["Therapeutics"] -->|"references"| APOE["APOE"]
Therapeutics["Therapeutics"] -->|"references"| VCP["VCP"]
Therapeutics["Therapeutics"] -->|"references"| GFAP["GFAP"]
Therapeutics["Therapeutics"] -->|"references"| NURR1["NURR1"]
Therapeutics["Therapeutics"] -->|"references"| BDNF["BDNF"]
Therapeutics["Therapeutics"] -->|"references"| NLRP3["NLRP3"]
Therapeutics["Therapeutics"] -->|"references"| TFEB["TFEB"]
Therapeutics["Therapeutics"] -->|"references"| PPARGC1A["PPARGC1A"]
style therapeutics fill:#4fc3f7,stroke:#333,color:#000
Lexeo Therapeutics is a clinical-stage gene therapy company headquartered at 345 Park Avenue South, 6th Floor, New York, NY 10010, focused on developing adeno-associated virus (AAV)-based gene therapies for genetically defined cardiovascular and neurodegenerative diseases. The company's neurodegenerative pipeline targets Alzheimer's disease and other tauopathies using gene therapy approaches.[@lexeo]
...Lexeo Therapeutics
Overview
Mermaid diagram (expand to render)
Lexeo Therapeutics is a clinical-stage gene therapy company headquartered at 345 Park Avenue South, 6th Floor, New York, NY 10010, focused on developing adeno-associated virus (AAV)-based gene therapies for genetically defined cardiovascular and neurodegenerative diseases. The company's neurodegenerative pipeline targets Alzheimer's disease and other tauopathies using gene therapy approaches.[@lexeo]
Lexeo retains exclusive worldwide development and commercialization rights to all product candidates.
| Attribute | Value |
|-----------|-------|
| Ticker | NASDAQ: LXEO |
| Founded | 2019 |
| Headquarters | New York, NY, USA |
| Focus | AAV gene therapy for genetic cardiovascular and CNS disorders |
| Status | Public company (IPO 2021) |
Funding History
| Year | Event | Amount |
|------|-------|--------|
| 2019 | Series A | ~$40 million |
| 2021 | IPO | ~$85 million |
| 2023 | Eli Lilly Partnership | Strategic |
| 2024 | Series C | $100+ million |
Clinical Pipeline
LX1001 (Lead CNS Program)
| Attribute | Value |
|-----------|-------|
| Target | APOE4 homozygous Alzheimer's disease |
| Gene Delivered | APOE2 (protective allele) |
| Delivery Route | Intrathecal (AAV) |
| Phase | Phase 1/2 (LEAD trial) |
| Designations | FDA Fast Track |
The flagship neurodegenerative program targets APOE4, the strongest genetic risk factor for late-onset Alzheimer's disease:[@apoe]
- Mechanism: Deliver a functional APOE2 gene (protective allele) to neurons
- Target: Patients homozygous for APOE4 (approximately 2-3% of AD cases)
- Delivery: Intrathecal (spinal) administration to achieve CNS delivery
- Status: Phase 1/2 ongoing (NCT03634007)
- Trial: LEAD trial (Lexeo Expression of APOE in Disease)
LX1021
| Attribute | Value |
|-----------|-------|
| Target | Alzheimer's Disease (Christchurch mutation) |
| Indication | APOE Christchurch carriers |
| Stage | Preclinical |
LX1020
| Attribute | Value |
|-----------|-------|
| Target | Alzheimer's Disease |
| Indication | APOE2+/E4- patients |
| Stage | Preclinical |
Cardiac Pipeline
LX2006 (Lead Cardiac Program)
| Attribute | Value |
|-----------|-------|
| Target | Friedreich Ataxia Cardiomyopathy |
| Gene | FXN (frataxin) |
| Phase | Phase 1/2 (SUNRISE-FA trial) |
| Designations | FDA Breakthrough Therapy, Regenerative Medicine Advanced Therapy, Orphan Drug, Rare Pediatric Disease |
LX2020
| Attribute | Value |
|-----------|-------|
| Target | Arrhythmogenic Cardiomyopathy |
| Gene | PKP2 |
| Stage | Preclinical |
LX2021
| Attribute | Value |
|-----------|-------|
| Target | Desmoplakin Cardiomyopathy |
| Gene | CX43 (Connexin 43) |
| Stage | Preclinical |
LX2022
| Attribute | Value |
|-----------|-------|
| Target | Hypertrophic Cardiomyopathy |
| Gene | TNNI3 (cardiac troponin I) |
| Stage | Preclinical |
Lexeo's gene therapy platform includes:
- AAV Vectors: Adeno-associated viruses for safe, long-term gene delivery
- CNS Delivery: Specialized delivery methods for brain-targeted therapies
- Gene Replacement: Delivering functional copies of disease-causing genes
- Gene Silencing: Using RNA interference for dominant-negative mutations
- cGMP Manufacturing: Internal manufacturing capabilities for clinical-scale production
Clinical Trials
Ongoing Trials
| Trial | Phase | Sponsor |
|-------|-------|---------|
| SUNRISE-FA | Phase 1/2 | Lexeo Therapeutics |
| LEAD (LX1001) | Phase 1/2 | Lexeo |
| Investigator-initiated Phase 1A | Phase 1 | Weill Cornell Medicine |
Supporting Studies
- CLARITY-FA: Natural history study for Friedreich Ataxia
- Weill Cornell Medicine investigator-initiated trial
APOE4 Biology
APOE4 carriers have significantly increased Alzheimer's risk:
- Homozygous APOE4: ~12x increased risk vs. APOE3
- Associated with increased amyloid deposition
- Impaired amyloid clearance
- Enhanced tau pathology
Key People
- R. Nolan Townsend (CEO)
- Dr. James M. (Co-founder and Chief Scientific Officer)
- Dr. Steven G. (Chief Medical Officer)
- Dr. Ronald G. (Co-founder and Chairman)
Partnerships
- Weill Cornell Medicine: Investigator-initiated trial collaboration
- Eli Lilly: Strategic partnership (2023)
Manufacturing
Lexeo operates internal cGMP manufacturing capabilities for AAV vector production, enabling clinical-scale manufacturing for their pipeline.
Cross-References
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- APOE Gene
- [Tau](/proteins/tau) Pathology](/mechanisms/tau-pathology)
- [Amyloid](/mechanisms/amyloid-aggregation) Pathology
- [Gene Therapy](/therapeutics/gene-therapy-neurodegeneration) Friedreich Ataxia
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/genes/ar)
- [APOE4](/diseases/apoe4)
External Links
- [Lexeo Therapeutics Website](https://www.lexeotx.com)
- [ClinicalTrials.gov - LX1001](https://clinicaltrials.gov/study/NCT03634007)
References
Unknown, Lexeo Therapeutics Website (n.d.)
[Unknown, APOE4 and Alzheimer's Disease Risk (n.d.)](https://pubmed.ncbi.nlm.nih.gov/26424828/)
[Unknown, APOE Gene Therapy for Alzheimer's (n.d.)](https://pubmed.ncbi.nlm.nih.gov/34148307/)See Also
- [Neuroinflammation and Microglia Pathway in Alzheimer's Disease](/wiki/mechanisms-ad-neuroinflammation-microglia-pathway) — inhibits